top of page

Azome announces exclusive patent license

March 6, 2023

Azome Therapeutics, an early-stage drug discovery company, announced the execution of an exclusive US patent license.  Under the agreement, Azome acquired exclusive rights to patent US10562935 entitled “Stapled peptides and uses thereof” and related EU patent applications. The intellectual property includes substantial and specific composition of matter and method of use protection for the company’s core RHAMM antagonist technology platform.


Commenting has been turned off.
bottom of page